Empagliflozin after Acute Myocardial Infarction
Javed Butler,W Schuyler Jones,Jacob A Udell,Stefan D Anker,Mark C Petrie,Josephine Harrington,Michaela Mattheus,Isabella Zwiener,Offer Amir,M Cecilia Bahit,Johann Bauersachs,Antoni Bayes-Genis,Yundai Chen,Vijay K Chopra,Gemma Figtree,Junbo Ge,Shaun G Goodman,Nina Gotcheva,Shinya Goto,Tomasz Gasior,Waheed Jamal,James L Januzzi,Myung Ho Jeong,Yuri Lopatin,Renato D Lopes,Béla Merkely,Puja B Parikh,Alexander Parkhomenko,Piotr Ponikowski,Xavier Rossello,Morten Schou,Dragan Simic,P Gabriel Steg,Joanna Szachniewicz,Peter van der Meer,Dragos Vinereanu,Shelley Zieroth,Martina Brueckmann,Mikhail Sumin,Deepak L Bhatt,Adrian F Hernandez
DOI: https://doi.org/10.1056/NEJMoa2314051
2024-04-25
Abstract:Background: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who have had acute myocardial infarction are unknown. Methods: In this event-driven, double-blind, randomized, placebo-controlled trial, we assigned, in a 1:1 ratio, patients who had been hospitalized for acute myocardial infarction and were at risk for heart failure to receive empagliflozin at a dose of 10 mg daily or placebo in addition to standard care within 14 days after admission. The primary end point was a composite of hospitalization for heart failure or death from any cause as assessed in a time-to-first-event analysis. Results: A total of 3260 patients were assigned to receive empagliflozin and 3262 to receive placebo. During a median follow-up of 17.9 months, a first hospitalization for heart failure or death from any cause occurred in 267 patients (8.2%) in the empagliflozin group and in 298 patients (9.1%) in the placebo group, with incidence rates of 5.9 and 6.6 events, respectively, per 100 patient-years (hazard ratio, 0.90; 95% confidence interval [CI], 0.76 to 1.06; P = 0.21). With respect to the individual components of the primary end point, a first hospitalization for heart failure occurred in 118 patients (3.6%) in the empagliflozin group and in 153 patients (4.7%) in the placebo group (hazard ratio, 0.77; 95% CI, 0.60 to 0.98), and death from any cause occurred in 169 (5.2%) and 178 (5.5%), respectively (hazard ratio, 0.96; 95% CI, 0.78 to 1.19). Adverse events were consistent with the known safety profile of empagliflozin and were similar in the two trial groups. Conclusions: Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov number, NCT04509674.).